Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Diabetes Mellitus
Interventions
DRUG

Pioglitazone and metformin

Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.

DRUG

Pioglitazone

Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.

DRUG

Metformin

Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.

Trial Locations (77)

Unknown

Birmingham

Haleyville

Montgomery

Pell City

Phoenix

Tucson

Anaheim

Artesia

Dinuba

Long Beach

Los Angeles

Norwalk

Orange

Santa Ana

Santa Monica

Pueblo

Altamonte Springs

Coral Gables

Hialeah

Miami

Panama City

Plantation

Saint Cloud

St. Petersburg

Tampa

Columbus

Boise

Coeur d'Alene

Chicago

Flossmoor

Peoria

Elkhart

Shawnee

Southfield

Chesterfield

Billings

Elizabeth

Fayetteville

New York

Durham

Pinehurst

Cincinnati

Perrysburg

Zanesville

Oklahoma City

Eugene

Fleetwood

Norristown

Cranston

Simpsonville

Varnville

Fayetteville

Corpus Christi

Dallas

El Paso

Houston

McAllen

Mission

New Braunfels

North Richland Hills

San Antonio

Bountiful

Salt Lake City

Petersburg

Port Orchard

Spokane

Providencia-Santiago

Temuco

Zapopan

Monterrey

Aibonito

Caguas

Ciales

Coto Laurel

Guayma

Guaynabo

Rio Piedras

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00727857 - Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus. | Biotech Hunter | Biotech Hunter